Other options are HBsAg inhibitors from Tekmira (TKMR), HBsAg release inhibitors from Replicor ... I am bullish ARWR, I hold the stock, and considering that in any list of HBV pipeline drug candidates, ARWR shows up as the most advanced in clinical ...
Seeking Alpha · 10/2/2015
HBV Treatment
NEW YORK (TheStreet) -- Shares of Tekmira Pharmaceuticals (TKMR) soared 46.27% to $22.97 in morning trading Monday after the company agreed to acquire OnCore Biopharma to shift focus to developing hepatitis B virus treatments by merging several …
The Street · 1/12/2015
However, one stock appears to be quietly gaining momentum on the headlines - Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). While a recent clinical study for Tekmira's Ebola virus RNAi therapeutic, TKM-Ebola, was placed on clinical hold by …
StreetInsider · 7/31/2014
More from Bing News
Shares of Tekmira Pharmaceuticals Corp (TKMR) are down 2.69% in mid-day trading after Glaucus Research downgraded its rating to “Strong Sell” recommendation, citing valuation concerns. “Tekmira is hugely overvalued and its share price is poised to ...
Wall Street Pit · 11/10/2014
Shares of Tekmira Pharmaceuticals Corporation NASDAQ:TKMR are trending higher once again. The stock soared a staggering 45% on Friday after the U.S. FDA loosened a hold on the company's Ebola treatment that is still in the development pipeline.
Value Walk · ByVikas Shukla · 8/11/2014
Tomahawk, WI 09/24/2014 (Basicsmedia) – Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) has announced that it will be ... to evaluate whether their drugs can be used in humans. Tekmira stock is the only one that has responded positively to the … · 9/24/2014
In a nutshell a bet on AXON stock is a bet against the expertise of GlaxoSmithKline, one of the largest pharmaceutical companies in the world, with a research and development budget topping $3.1 billion last year. TKMR stock is not profitable and trades ...
Investor Place · 6/12/2015
These stocks are declining the most during NASDAQ PRE-MARKET trading as of Monday, October 6, 2014. Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) now trades at $2.3, down -65.4 percent in Pre-Market sessions on 764960 total share volume.
Fx Pips · 10/6/2014
we don’t believe there is significant read-through to TKMR’s other programs, including the HBV program, which we view as the main value driver for the stock long-term. We currently only attribute $1 (3%) of our $30 valuation to TKM-Ebola.”
Smallcap Network · ByJohn Udovich · 6/22/2015
One trader, Dave Lutz of Jones Trading, has compiled a list of stocks that are either directly impacted or could be affected by the spread of Ebola. Canadian biotech firm Tekmira Pharmaceuticals (TKMR)' stock surged in September after the FDA authorized ...
CNN Money · ByBen Rooney · 10/24/2014